MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells

被引:0
|
作者
Boucher, MJ
Morisset, J
Vachon, PH
Reed, JC
Lainé, J
Rivard, N [1 ]
机构
[1] Univ Sherbrooke, Fac Med, Dept Anat & Biol Cellulaire, Grp Conseil Rech Med Dev Fonct & Physiopathol Tub, Sherbrooke, PQ J1H 5N4, Canada
[2] Univ Sherbrooke, Fac Med, Serv Gastroenterol, Sherbrooke, PQ J1H 5N4, Canada
[3] Burnham Inst, La Jolla, CA 92037 USA
关键词
D O I
10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background and aims: Growth factors are well known for their participation in the regulation of cell proliferation and survival. However, the intracellular signaling pathways by which growth factors promote survival are still poorly understood. In the present study, using the MIA PaCa-2 cell line, a well-established model of pancreatic cancer cells, we analyzed the roles of ERK1/2 activities in the regulation of cell survival and investigated some of the mechanisms involved. Methods: The ability of the MEK inhibitor PD98059 to modulate survival of the MIA PaCa-2 cells was Evaluated, and the responses were correlated with expression of Bcl-2 homologs and caspases 1, 3, 6, 8, and 9 activities. Results. Herein, we showed that inhibition of ERK1/2 activities caused (1) a G1 arrest; (2) a down-regulation of the expression levels of the anti-apoptotic homologs Bcl-2, Mcl-1, and Bcl-X-L without affecting the pro-apoptotic levels of Bax and Bak; (3) a promotion of caspases 3, 6, 8, and 9 activities; (4) a stimulation of PARP cleavage; and (5) a programmed cell death by apoptosis. Conclusion: Our data suggest that activation of the ERK pathway functions to protect pancreatic tumor cells from apoptosis as well as to regulate their progression in the cell cycle. (C) 2000 Wiley-Liss, Inc.
引用
收藏
页码:355 / 369
页数:15
相关论文
共 50 条
  • [1] BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
    Erinna F. Lee
    Tiffany J. Harris
    Sharon Tran
    Marco Evangelista
    Surein Arulananda
    Thomas John
    Celeste Ramnac
    Chloe Hobbs
    Haoran Zhu
    Gency Gunasingh
    David Segal
    Andreas Behren
    Jonathan Cebon
    Alexander Dobrovic
    John M. Mariadason
    Andreas Strasser
    Leona Rohrbeck
    Nikolas K. Haass
    Marco J. Herold
    W. Douglas Fairlie
    Cell Death & Disease, 10
  • [2] BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
    Lee, Erinna F.
    Harris, Tiffany J.
    Tran, Sharon
    Evangelista, Marco
    Arulananda, Surein
    John, Thomas
    Ramnac, Celeste
    Hobbs, Chloe
    Zhu, Haoran
    Gunasingh, Gency
    Segal, David
    Behren, Andreas
    Cebon, Jonathan
    Dobrovic, Alexander
    Mariadason, John M.
    Strasser, Andreas
    Rohrbeck, Leona
    Haass, Nikolas K.
    Herold, Marco J.
    Fairlie, W. Douglas
    CELL DEATH & DISEASE, 2019, 10
  • [3] Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade
    Williams, Michelle M.
    Lee, Linus
    Hicks, Donna J.
    Joly, Meghan M.
    Elion, David
    Rahman, Bushra
    McKernan, Courtney
    Sanchez, Violeta
    Balko, Justin M.
    Stricker, Thomas
    Estrada, Monica Valeria
    Cook, Rebecca S.
    MOLECULAR CANCER RESEARCH, 2017, 15 (03) : 259 - 268
  • [4] Bcl-2 and Bcl-xL Suppress Glucose Signaling in Pancreatic β-Cells
    Luciani, Dan S.
    White, Sarah A.
    Widenmaier, Scott B.
    Saran, Varun V.
    Taghizadeh, Farnaz
    Hu, Xiaoke
    Allard, Michael F.
    Johnson, James D.
    DIABETES, 2013, 62 (01) : 170 - 182
  • [5] Evaluation of Mcl-1, Bcl-xL, Bcl-2 Expression as Potential Therapeutic Targets for Colorectal Adenocarcinoma
    Dermawan, Josephine
    Demelash, Abeba
    Gastman, Brian
    Mayell, Cameron
    Pfannenstiel, Lukas
    Kalady, Matthew
    DeVecchio, Jennifer
    Patil, Deepa T.
    MODERN PATHOLOGY, 2018, 31 : 258 - 258
  • [6] Evaluation of Mcl-1, Bcl-xL, Bcl-2 Expression as Potential Therapeutic Targets for Colorectal Adenocarcinoma
    Dermawan, Josephine
    Demelash, Abeba
    Gastman, Brian
    Mayell, Cameron
    Pfannenstiel, Lukas
    Kalady, Matthew
    DeVecchio, Jennifer
    Patil, Deepa T.
    LABORATORY INVESTIGATION, 2018, 98 : 258 - 258
  • [7] Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors
    Peng, Zhe
    Gillissen, Bernhard
    Richter, Antje
    Sinnberg, Tobias
    Schlaak, Max S.
    Eberle, Juergen
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [8] The expression of antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1 in benign, dysplastic, and malignant biliary epithelium
    Okaro, AC
    Deery, AR
    Hutchins, RR
    Davidson, BR
    JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (12) : 927 - 932
  • [9] Mcl-1 and Bcl-xL coordinately regulate megakaryocyte survival
    Debrincat, Marlyse A.
    Josefsson, Emma C.
    James, Chloe
    Henley, Katya J.
    Ellis, Sarah
    Lebois, Marion
    Betterman, Kelly L.
    Lane, Rachael M.
    Rogers, Kelly L.
    White, Michael J.
    Roberts, Andrew W.
    Harvey, Natasha L.
    Metcalf, Donald
    Kile, Benjamin T.
    BLOOD, 2012, 119 (24) : 5850 - 5858
  • [10] Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK/Bcl-2 inhibition in B-cell malignancies
    Melvold, Katrine
    Giliberto, Mariaserena
    Karlsen, Linda
    Ayuda-Duran, Pilar
    Hanes, Robert
    Holien, Toril
    Enserink, Jorrit
    Brown, Jennifer R.
    Tjonnfjord, Geir E.
    Tasken, Kjetil
    Skanland, Sigrid S.
    MOLECULAR ONCOLOGY, 2022, 16 (05) : 1153 - 1170